Taha Sen

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

Taha Sen, Jingwei Li, Brendon L. Neuen et al. · Diabetologia · 2021 · 80 citations · Full text

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Akihiko Koshino, Meir Schechter, Taha Sen et al. · Diabetes Care · 2022 · 51 citations · Full text

Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

Simke W. Waijer, Taha Sen, Clare Arnott et al. · Clinical Journal of the American Society of Nephrology · 2021 · 46 citations · Full text

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>

Taha Sen, Rosalie A. Scholtes, Peter J. Greasley et al. · Diabetes Obesity and Metabolism · 2022 · 32 citations · Full text

Mechanisms of action of the sodium‐glucose cotransporter‐2 ( <scp>SGLT2)</scp> inhibitor canagliflozin on tubular inflammation and damage: A <i>post hoc mediation</i> analysis of the <scp>CANVAS</scp> trial

Taha Sen, Akihiko Koshino, Bruce Neal et al. · Diabetes Obesity and Metabolism · 2022 · 26 citations · Full text